JPRN-UMIN000003673已完成未知
FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study - FOLFOX and bevacizumab alternated with sLV5FU2 and bevacizumab for patients with metastatic colorectal cancer
niversity of Toyama0 个研究点目标入组 20 人开始时间: 2010年5月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Brain metastasis 2. Massive pleural effusion or ascites 3. Active other malignancies 4. Nonhealing wound 5. Surgical procedure within 28 days before registration 6. Severe complications(bowel obstruction, symptomatic cardiovascular disease, interstitial pneumonitis, pulmonary fibrosis, uncontrollable hepertension, uncontrollable diabetes mellitus, active peptic ulcer, bleeding diathesis) 7. History of thromboembolitic disease 8. Uncontrollable diarrhea 9. Administration of corticosteroids 10. Administration of anticoagulants 11. Peripheral neuropathy 12. Active infectious disease 13. History of severe drug hypersensitivity 14. Psychosis 15. Pregnant or breast-feeding women 16. Men of wishing fertility 17. Not appropriate for the study at the physician's assessmnt
研究者
相似试验
进行中（未招募）
不适用
Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer - NDEUCTR2006-001779-39-ITAzienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
已完成
2 期
Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.JPRN-UMIN000002378Japan South West Oncology Group45
进行中（未招募）
不适用
Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study. - GOIM 2802Oncologic patientsMedDRA version: 13.1Level: LLTClassification code 10001167Term: Adenocarcinoma of colonSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022091-31-ITGOIM GRUPPO ONCOLOGICO MERIDIONALE
进行中（未招募）
不适用
Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment lineEUCTR2014-004436-19-ITG.O.N.O.
进行中（未招募）
1 期
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer.metastatic colorectal cancerMedDRA version: 20.0Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004434-26-DEAIO-Studien-gGmbH43